GSK vs. AZN, HLN, SN, CTEC, HIK, HCM, INDV, GNS, SPI, and ONT
Should you be buying GSK stock or one of its competitors? The main competitors of GSK include AstraZeneca (AZN), Haleon (HLN), Smith & Nephew (SN), ConvaTec Group (CTEC), Hikma Pharmaceuticals (HIK), HUTCHMED (HCM), Indivior (INDV), Genus (GNS), Spire Healthcare Group (SPI), and Oxford Nanopore Technologies (ONT). These companies are all part of the "medical" sector.
AstraZeneca (LON:AZN) and GSK (LON:GSK) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.
AstraZeneca presently has a consensus price target of £116.86, indicating a potential downside of 2.52%. GSK has a consensus price target of GBX 1,630.63, indicating a potential downside of 1.35%. Given AstraZeneca's higher possible upside, analysts clearly believe GSK is more favorable than AstraZeneca.
In the previous week, AstraZeneca and AstraZeneca both had 4 articles in the media. GSK's average media sentiment score of 0.36 beat AstraZeneca's score of 0.02 indicating that AstraZeneca is being referred to more favorably in the media.
GSK has a net margin of 16.25% compared to GSK's net margin of 13.00%. AstraZeneca's return on equity of 46.38% beat GSK's return on equity.
AstraZeneca pays an annual dividend of GBX 228 per share and has a dividend yield of 1.9%. GSK pays an annual dividend of GBX 64 per share and has a dividend yield of 3.9%. AstraZeneca pays out 7,524.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. GSK pays out 5,333.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. GSK is clearly the better dividend stock, given its higher yield and lower payout ratio.
50.8% of AstraZeneca shares are owned by institutional investors. Comparatively, 45.4% of GSK shares are owned by institutional investors. 0.2% of AstraZeneca shares are owned by company insiders. Comparatively, 1.7% of GSK shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
AstraZeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.
AstraZeneca received 769 more outperform votes than GSK when rated by MarketBeat users. Likewise, 63.61% of users gave AstraZeneca an outperform vote while only 50.21% of users gave GSK an outperform vote.
AstraZeneca has a beta of 0.19, indicating that its stock price is 81% less volatile than the S&P 500. Comparatively, GSK has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500.
Summary
AstraZeneca beats GSK on 11 of the 19 factors compared between the two stocks.
Get GSK News Delivered to You Automatically
Sign up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GSK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
